Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2020 Sep 23

PMID 32964055

Citations 6

Authors

Lichen Zhu

Xiaomei Yang

Dani Zhong

Shenxia Xie

Wei Shi

Yangzi Li

Xiaoqiong Hou

HuaYao

Huihui Zhou

Minlong Zhao

Ziqiang Ding

Xinyue Zhao

Fengzhen Mo

Shihua Yin

Aiqun Liu

Xiaoling Lu

Affiliations

Soon will be listed here.

Abstract

Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited. With the exception of the commercialized CD19 CAR-T for hematological malignancies and other CAR-T therapies aiming mostly at extracellular antigens achieving great success, the rareness and scarcity of TCR-like CAR-T therapies might be due to their current status and limitations. This review provides the probable optimized initiatives for improving TCR-like CAR-T reprogramming and discusses single-domain antibodies administered as an alternative to conventional scFvs and secreted by CAR-T cells, which might be of great value to the development of CAR-T immunotherapies for intracellular antigens.

Citing Articles

Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs.

Guo S, Xi X Biomark Res. 2025; 13(1):41.

PMID: 40069884 PMC: 11899093. DOI: 10.1186/s40364-025-00755-5.

Antigen-specific modulation of chronic experimental autoimmune encephalomyelitis in humanized mice by TCR-like antibody targeting autoreactive T-cell epitope.

Goor A, Altman E, Arman I, Erez S, Haus-Cohen M, Reiter Y Life Sci Alliance. 2024; 8(1).

PMID: 39496501 PMC: 11536346. DOI: 10.26508/lsa.202402996.

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.

Temple W, Nix M, Naik A, Izgutdina A, Huang B, Wicaksono G J Immunother Cancer. 2023; 11(11).

PMID: 38007238 PMC: 10680002. DOI: 10.1136/jitc-2023-006985.

Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.

Kirkey D, Loeb A, Castro S, McKay C, Perkins L, Pardo L Blood Adv. 2022; 7(7):1178-1189.

PMID: 35984639 PMC: 10111362. DOI: 10.1182/bloodadvances.2022008304.

TCR-like antibodies targeting autoantigen-mhc complexes: a mini-review.

Li Y, Jiang W, Mellins E Front Immunol. 2022; 13:968432.

PMID: 35967436 PMC: 9363607. DOI: 10.3389/fimmu.2022.968432.

References

Yewdell J . Plumbing the sources of endogenous MHC class I peptide ligands. Curr Opin Immunol. 2006; 19(1):79-86. DOI: 10.1016/j.coi.2006.11.010. View

Vu K, Ghahroudi M, Wyns L, Muyldermans S . Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol. 1998; 34(16-17):1121-31. DOI: 10.1016/s0161-5890(97)00146-6. View

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J . Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006; 103(12):4586-91. PMC: 1450215. DOI: 10.1073/pnas.0505379103. View

Salvador J, Vilaplana L, Marco M . Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019; 411(9):1703-1713. DOI: 10.1007/s00216-019-01633-4. View

Liu W, Song H, Chen Q, Yu J, Xian M, Nian R . Recent advances in the selection and identification of antigen-specific nanobodies. Mol Immunol. 2018; 96:37-47. DOI: 10.1016/j.molimm.2018.02.012. View

Danquah W, Meyer-Schwesinger C, Rissiek B, Pinto C, Serracant-Prat A, Amadi M . Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci Transl Med. 2016; 8(366):366ra162. DOI: 10.1126/scitranslmed.aaf8463. View

Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-Iba S, Endoh A . Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Ther. 2014; 21(6):575-84. DOI: 10.1038/gt.2014.30. View

Dass S, Norazmi M, Acosta A, Sarmiento M, Tye G . TCR-like domain antibody against Mycobacterium tuberculosis (Mtb) heat shock protein antigen presented by HLA-A*11 and HLA-A*24. Int J Biol Macromol. 2020; 155:305-314. DOI: 10.1016/j.ijbiomac.2020.03.229. View

10.

Ellis J, Henson V, Slack R, Ng J, Hartzman R, Katovich Hurley C . Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. Hum Immunol. 2000; 61(3):334-40. DOI: 10.1016/s0198-8859(99)00155-x. View

11.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

12.

Pirooznia N, Hasannia S, Taghdir M, Rahbarizadeh F, Eskandani M . The construction of chimeric T-Cell receptor with spacer base of modeling study of VHH and MUC1 interaction. J Biomed Biotechnol. 2011; 2011:578128. PMC: 3160013. DOI: 10.1155/2011/578128. View

13.

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

14.

Rahbarizadeh F, Ahmadvand D, Moghimi S . CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev. 2019; 141:41-46. DOI: 10.1016/j.addr.2019.04.006. View

15.

van der Linden R, Frenken L, de Geus B, Harmsen M, Ruuls R, Stok W . Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta. 1999; 1431(1):37-46. DOI: 10.1016/s0167-4838(99)00030-8. View

16.

Stephan M, Ponomarev V, Brentjens R, Chang A, Dobrenkov K, Heller G . T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007; 13(12):1440-9. DOI: 10.1038/nm1676. View

17.

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

18.

Migliorini D, Dietrich P, Stupp R, Linette G, Posey Jr A, June C . CAR T-Cell Therapies in Glioblastoma: A First Look. Clin Cancer Res. 2017; 24(3):535-540. DOI: 10.1158/1078-0432.CCR-17-2871. View

19.

Garrido F, Cabrera T, Aptsiauri N . "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer. 2010; 127(2):249-56. DOI: 10.1002/ijc.25270. View

20.

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K . Nanobody Based Dual Specific CARs. Int J Mol Sci. 2018; 19(2). PMC: 5855625. DOI: 10.3390/ijms19020403. View